AUTHORS
Yuntong Liu, Jian Cui, MD, PhD2, Lihui Shi3, Hesong Zou4, Weiwei Sui5, Lu-Gui Qiu, PhD6, Gang An, MD7
AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
7 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
ABSTRACT
Background: Patients with newly diagnosed multiple myeloma (NDMM) harboring TP53 abnormalities remain at high risk of early relapse despite intensive frontline therapy. We designed a sequential strategy comprising BCMA-directed CAR T-cell infusion (CAR T1), autologous stem cell transplantation (ASCT), and a second CAR T-cell infusion (CAR T2) to integrate complementary mechanisms: CAR T1 for rapid immune-mediated cytoreduction, high-dose melphalan/ASCT for non-cross-resistant eradication of residual disease, and CAR T2 to renew BCMA-directed immune pressure during post-transplant lymphopenic immune reconstitution, potentially clearing residual myeloma cells in the graft or bone marrow and establishing immune surveillance.
Methods: This prospective, single-center, single-arm phase 2 trial (NCT05850286) enrolled transplant-eligible patients aged 18-65 years with NDMM and del(17p) and/or TP53 mutation. After 3-4 cycles of VRd-based induction, patients underwent separate collections for CAR T-cell manufacturing and ASCT. Patients received lymphodepletion and CAR T1, followed by consolidation. High-dose melphalan (200 mg/m²) and ASCT were followed by CAR T2 on day +2 or +3; lenalidomide-based maintenance began approximately day +100. The primary endpoint was complete response rate (CRR). Measurable residual disease (MRD) was assessed by next-generation flow (NGF, sensitivity <10-5). Data cutoff was April 15, 2026.
Results: Twenty-two patients were enrolled; 20 received CAR T1, 18 underwent ASCT, and 16 received CAR T2. In the infused cohort (n = 20), median age was 59 years (range, 40-65), and 55.0% were male; 95.0% had del(17p), 37.5% of patients had TP53 mutation, 31.3% had biallelic TP53 inactivation and 80.0% had double-hit cytogenetics. CAR T1 markedly deepened response: CRR increased from 45.0% after induction to 80.0% at 3 months after CAR T1, while NGF-MRD negativity increased from 35.0% to 95.0%. At 3 months after ASCT/CAR T2, CRR was 94.4% (17/18) and NGF-MRD negativity was 82.4% (14/17). All 20 infused patients achieved stringent complete response and NGF-MRD negativity as their best response. After a median follow-up of 23.4 months (range, 7.5-35.2), 3 patients had progressed and no deaths had occurred. Median progression-free survival (PFS) and overall survival were not reached; estimated 24-month PFS was 87.1% (95% CI, 71.8%-100.0%). Cytokine release syndrome occurred in 45.0% after CAR T1 and 37.5% after CAR T2; all events were grade 1 or 2. No immune effector cell-associated neurotoxicity syndrome, grade ≥3 CRS, or treatment-related deaths occurred. CAR transgene expansion was detected after both infusions, with median Cmax values of 55,807 and 9,713 copies/µg genomic DNA after CAR T1 and CAR T2, respectively.
Conclusion: In transplant-eligible NDMM with TP53 abnormalities, the CAR T1-ASCT-CAR T2 strategy produced rapid and deep responses, with all infused patients achieving sCR and NGF-MRD negativity as their best response. The estimated 24-month PFS was 87.1%, and toxicity was manageable. These findings support the feasibility and preliminary activity of integrating sequential BCMA-directed CAR T-cell therapy with ASCT and warrant confirmation in larger, controlled multicenter studies.
DISCLOSURES
Yuntong Liu: No relevant conflicts of interest to declare.